Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Retrieved on: 2025-03-05 07:34:25

Tags for this article:

Genmab

Daratumumab

Short

Stock valuation

Marketbeat

Click the tags to see associated articles and topics

Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages. View article details on hiswai:

Summary

The article discusses Genmab A/S's stock valuation, highlighting various analyst ratings and its performance in capital markets. It emphasizes institutional investments and Genmab's role in developing Daratumumab. This connects to the tags and 'capital markets' concept.

Article found on: www.defenseworld.net

View Original Article